Michael Rome's most recent trade in Kinnate Biopharma Inc was a trade of 20,250 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 13, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Kinnate Biopharma Inc | Michael Rome | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 20,250 | 20,250 | - | - | Stock Option (right to buy) | |
Kinnate Biopharma Inc | Michael Rome | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 40,501 | 40,501 | - | - | Stock Option (right to buy) |